Table 2.
Baseline table.
| Characteristics | Overall | Survivors | Nonsurvivors | P value |
|---|---|---|---|---|
| n (%) | 341 (100%) | 260 (76.2%) | 81 (23.8%) | |
| Sociodemographics | ||||
| Age, years (median, IQR) | 68 (60, 75) | 68 (58, 75) | 69 (61, 75) | 0.20 |
| Male gender, n (%) | 208 (61.0%) | 162 (62.3%) | 46 (56.8%) | 0.37 |
| Diagnosis at ED admission, n (%) | ||||
| Infection | 208 (61.0%) | 152 (58.5%) | 56 (69.1%) | 0.016 |
| Gastrointestinal disease | 14 (4.1%) | 12 (4.6%) | 2 (2.5%) | |
| Cardiovascular disease | 42 (12.3%) | 37 (14.2%) | 5 (6.2%) | |
| Worsening of general condition | 2 (0.6%) | 2 (0.8%) | 0 (0.0%) | |
| Neurological disease | 50 (14.7%) | 33 (12.7%) | 17 (21.0%) | |
| Other diseases | 25 (7.3%) | 24 (9.2%) | 1 (1.2%) | |
| Main symptom at ED admission, n (%) | ||||
| General malaise | 60 (17.8%) | 40 (15.5%) | 20 (25.3%) | 0.46 |
| Pain | 48 (14.2%) | 39 (15.1%) | 9 (11.4%) | |
| Gastrointestinal symptom | 84 (24.9%) | 65 (25.2%) | 19 (24.1%) | |
| Neurological symptom | 44 (13.1%) | 36 (14.0%) | 8 (10.1%) | |
| Fever | 55 (16.3%) | 43 (16.7%) | 12 (15.2%) | |
| Respiratory symptom | 46 (13.6%) | 35 (13.6%) | 11 (13.9%) | |
| Primary cancer site, n (%) | ||||
| Solid cancers | 276 (80.9%) | 207 (75%) | 69 (25%) | |
| Gastrointestinal tract | 88 (25.8%) | 64 (24.6%) | 24 (29.6%) | 0.27 |
| Respiratory tract | 76 (22.3%) | 51 (19.6%) | 25 (30.9%) | |
| Bones, joints, cartilage | 6 (1.8%) | 6 (2.3%) | 0 (0.0%) | |
| Skin | 5 (1.5%) | 4 (1.5%) | 1 (1.2%) | |
| Genital, testis, urogenital | 58 (17.0%) | 46 (17.7%) | 12 (14.8%) | |
| Brain and nervous system | 43 (12.6%) | 36 (13.8%) | 7 (8.6%) | |
| Haematological cancers | 60 (17.6%) | 49 (81.7%) | 11 (18.3%) | |
| Hodgkin's lymphoma | 4 (1.2%) | 4 (1.5%) | 0 (0.0%) | |
| Non-Hodgkin's lymphoma | 20 (5.9%) | 17 (6.5%) | 3 (3.7%) | |
| Multiple myeloma | 13 (3.8%) | 12 (4.6%) | 1 (1.2%) | |
| Leukaemia (acute and chronic) | 23 (6.7%) | 16 (6.2%) | 7 (8.6%) | |
| Not specified or other | 5 (1.5%) | 4 (1.5%) | 1 (1.2%) | |
| Comorbidities, n (%) | ||||
| Renal failure | 65 (19.1%) | 46 (17.7%) | 19 (23.5%) | 0.25 |
| Diabetes mellitus | 46 (13.5%) | 36 (13.8%) | 10 (12.3%) | 0.73 |
| COPD | 32 (9.4%) | 22 (8.5%) | 10 (12.3%) | 0.30 |
| Coronary heart disease | 20 (5.9%) | 16 (6.2%) | 4 (4.9%) | 0.68 |
| Congestive heart failure | 10 (2.9%) | 5 (1.9%) | 5 (6.2%) | 0.05 |
| Blood biomarkers, median (IQR) | ||||
| CRP (mg/L) | 37.2 (9, 107) | 28.35 (7.9, 85.9) | 98 (23.2, 161) | <0.001 |
| Albumin (g/L) | 31.7 (26.5, 36.6) | 33.3 (29, 37.1) | 26 (21.6, 31.4) | <0.001 |
| WBC (109/L) | 8.3 (5.4, 11.7) | 7.9 (5, 11.2) | 9.2 (6.3, 13.2) | 0.049 |
| PCT (μg/L) | 0.14 (0.08, 0.33) | 0.13 (0.08, 0.24) | 0.28 (0.11, 0.69) | <0.001 |
| Urea (mmol/L) | 6.3 (4.7, 9) | 6.2 (4.5, 8.7) | 6.4 (5.3, 11.8) | 0.062 |
| 25(OH) vitamin D (nmol/L) | 42.2 (24.6, 61.7) | 44.9 (27.4, 64) | 32.2 (19.9, 47.6) | <0.001 |
| Corr Ca (mmol/L) | 2.39 (2.28, 2.51) | 2.36 (2.26, 2.46) | 2.47 (2.35, 2.66) | <0.001 |
WBC: white blood cell count; PCT: procalcitonin; 25(OH) vitamin D: 25-hydroxyvitamin D; corr Ca: corrected calcium; COPD: chronic obstructive pulmonary disease.